Vitro Biopharma

Cell & Gene Therapy · Biotechnology

Overview

Vitro Biopharma is an innovative biotechnology company focused on developing Wharton's jelly-derived cell therapies for autoimmune diseases and inflammatory disorders.

Funding and backers

Total raised
$1.2M
7 rounds on record
Latest round
$100k
Venture round · May 2025 · 17 mo ago
Team
11-50
employees, estimated range
The money's age
Due for its next round
17 months since the last round · not hiring
Momentum
0/100
no fresh signals
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
May 27, 2025 Raised a round Venture round $100k · SEC Form D Nov 16, 2023 Took on debt financing $2M · SEC Form D Jan 6, 2023 Took on debt financing $993k · SEC Form D Oct 15, 2021 Took on debt financing $3M · SEC Form D Jan 15, 2020 Raised a round Venture round $1M · SEC Form D Sep 17, 2010 Raised a round Venture round $30k · SEC Form D Dec 18, 2009 Raised a round Venture round $88k · SEC Form D
Funding rounds
RoundDateAmountInvestorsSource
Venture round May 2025 $100k — SEC Form D
Debt Financing Nov 2023 $2M — SEC Form D
Debt Financing Jan 2023 $993k — SEC Form D
Debt Financing Oct 2021 $3M — SEC Form D
Venture round Jan 2020 $1M — SEC Form D
Venture round Sep 2010 $30k — SEC Form D
Venture round Dec 2009 $88k — SEC Form D
Registers and programsofficial lists and records that name the company
Legal entity Vitro Biopharma, Inc. SEC Form D
Founders and leadersfrom filings, registers and the company's site
Chris FurmanExecutive Officer, DirectorSEC Form D
Thomas OhrtExecutive OfficerSEC Form D
Investors in similar startupsfunds that back the companies most like this one
Y Combinator
backs LEAH Labs
General Catalyst
backs Waypoint Bio
GV
backs Sonoma Biotherapeutics
8VC
backs Sonoma Biotherapeutics
Hummingbird Ventures
backs Waypoint Bio
CIC
backs Complement Therapeutics
Similar startupsby what they do, their industry and backers
MediSix Therapeutics
MediSix Therapeutics develops innovative T-cell therapies using its proprietary PEBL technology platform. An IASO Biotechnology subsidiary.
LEAH LabsFounded 2018 · 11-50 employees
Designer cell therapies for pets first and their people next.
CARTemis Therapeutics GmbH
Next-generation CAR T-cell therapies engineered to disrupt the tumor microenvironment OUR MISSION CARTemis Therapeutics is a clinical-stage…
Calycia Bioscience
Pioneering Cell Therapies for the Central Nervous System. We are a Salt Lake City-based biotechnology company developing novel macrophage…
Waypoint Bio11-50 employees
Waypoint Bio is a biotechnology company pioneering the next generation of cell therapies for solid tumors.
Sonoma Biotherapeutics
Search for: At SonomaBio we believe in balance. Sonoma Biotherapeutics is a clinical-stage biotechnology company developing engineered…

Financials

Total raised
$7.2M
Latest round
Venture - Series Unknown
Funding rounds
7
Funding rounds
Round Announced Amount
Venture - Series Unknown 2025 $100k Details
Debt Financing 2023 $2M Details
Debt Financing 2023 $993k Details
Debt Financing 2021 $3M Details
Venture - Series Unknown 2020 $1M Details
Venture - Series Unknown 2010 $30k Details
Venture - Series Unknown 2009 $88k Details

People

Chris Furman
Executive Officer, Director
SEC Form D
Thomas Ohrt
Executive Officer
SEC Form D
John Packs
Director
SEC Form D
James Musick
Director
SEC Form D
Caroline Mosessian
Director
SEC Form D
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data

Offices

Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Golden United States
HQ
Vitro Biopharma, Inc.
10-50 est. staff
4621 Technology Drive, Golden, CO 80403
company site